You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 7, 2025

Details for Patent: 10,668,040


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,668,040 protect, and when does it expire?

Patent 10,668,040 protects RAVICTI and is included in one NDA.

Summary for Patent: 10,668,040
Title:Treatment of urea cycle disorders in neonates and infants
Abstract: Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-PAGN and plasma PAA:PAGN ratio.
Inventor(s): Scharschmidt; Bruce (San Francisco, CA), Mokhtarani; Masoud (Walnut Creek, CA)
Assignee: Horizon Therapeutics, LLC (Lake Forest, IL)
Application Number:16/128,140
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,668,040

Introduction

When analyzing a patent, particularly one like United States Patent 10,668,040, it is crucial to delve into the scope and claims of the patent to understand its significance, limitations, and potential impact. This article will provide a detailed analysis of the patent landscape surrounding this specific patent.

Patent Overview

United States Patent 10,668,040, assigned to Horizon Therapeutics LLC, pertains to the "Treatment of Urea Cycle Disorders in Neonates and Infants." This patent addresses a critical medical need by providing innovative treatments for urea cycle disorders, which are genetic conditions that can lead to severe health complications if not managed properly.

Claim Scope

The claim scope of a patent is pivotal in defining the boundaries of the invention and the protection it offers. Here are some key points to consider:

Broad vs. Specific Claims

A common misconception is that broader claims are always better. However, as highlighted in the context of patent applications, broader claims can be more difficult to get granted and are easier to invalidate[3].

  • For Patent 10,668,040, the claims must be carefully crafted to ensure they are not overly broad, which could lead to invalidation due to abstract idea exceptions or failure to meet the written description requirement.

Anchoring Claims to Embodiments

Claims in a patent application must be anchored to the embodiments described in the specification. This ensures that the claims are supported by the disclosure and are not overly broad or vague[3].

Example Claims

To illustrate, if a claim in Patent 10,668,040 reads: "A method for treating urea cycle disorders in neonates and infants comprising administering a specific dosage of a pharmaceutical compound," it must be supported by detailed descriptions in the specification of how this method works, the specific dosage, and the pharmaceutical compound involved.

Prior Art and Patent Landscape

Understanding the prior art and the broader patent landscape is essential for assessing the novelty and non-obviousness of the invention.

Searching Prior Art

To determine if an invention is novel, one must conduct a thorough search of prior art. Tools like the USPTO's Patent Public Search, Global Dossier, and international patent databases such as those provided by the European Patent Office (EPO) and the World Intellectual Property Organization (WIPO) are invaluable for this purpose[1].

International Patent Offices

Since patent protection is often sought in multiple countries, it is crucial to search international patent databases to ensure that the invention has not been previously patented abroad. For example, the EPO's esp@cenet and WIPO's PATENTSCOPE can provide insights into similar patents filed in other jurisdictions[1].

Patent Quality and Examination

The quality of a patent is a critical factor in its validity and enforceability.

Definition of Patent Quality

The USPTO defines a quality patent as one that is correctly issued in compliance with all the requirements of Title 35 of the U.S. Code and relevant case law at the time of issuance. This includes meeting statutory requirements for novelty, clarity, and non-obviousness[4].

Examination Process

The examination process for Patent 10,668,040 would have involved a thorough review by USPTO examiners to ensure that the claims meet these statutory requirements. The USPTO has implemented various initiatives, such as the Enhanced Patent Quality Initiative, to improve the quality of patents issued[4].

Legal Framework and Court Decisions

The legal framework surrounding patents, particularly in the United States, is constantly evolving.

Abstract Idea Exception

The abstract idea exception, as established by the Supreme Court in the Alice decision, is a significant consideration. Claims that are too broad and merely invoke generic processes or machinery without improving the relevant technology can be invalidated under this exception[3].

Recent Court Decisions

Cases like Yu v. Apple Inc. and Minerva Surgical, Inc. v. Hologic, Inc. provide valuable insights into how courts interpret claim scope and the risks associated with overly broad claims. These decisions highlight the importance of carefully drafting claims to avoid invalidation[3].

Practical Implications

For Horizon Therapeutics LLC and other stakeholders, the practical implications of the scope and claims of Patent 10,668,040 are significant.

Market Protection

The patent provides exclusive rights to Horizon Therapeutics LLC to market and sell the treatment for urea cycle disorders, protecting their investment in research and development.

Licensing and Collaboration

The patent can also serve as a basis for licensing agreements or collaborations with other pharmaceutical companies, further expanding the reach of the treatment.

Key Takeaways

  • Claim Scope: The claims of Patent 10,668,040 must be carefully balanced between being broad enough to offer meaningful protection and specific enough to avoid invalidation.
  • Prior Art: A thorough search of prior art is essential to ensure the novelty and non-obviousness of the invention.
  • Patent Quality: The patent must meet all statutory requirements and be issued in compliance with relevant case law to ensure its quality and validity.
  • Legal Framework: The abstract idea exception and recent court decisions underscore the importance of precise claim drafting.
  • Practical Implications: The patent provides market protection and can facilitate licensing and collaboration opportunities.

FAQs

Q1: What is the main subject of United States Patent 10,668,040? A1: The main subject of United States Patent 10,668,040 is the treatment of urea cycle disorders in neonates and infants.

Q2: Why is the claim scope important in a patent application? A2: The claim scope defines the boundaries of the invention and the protection it offers. It must be balanced to avoid being too broad or too narrow.

Q3: How does the USPTO ensure patent quality? A3: The USPTO ensures patent quality through initiatives like the Enhanced Patent Quality Initiative, which includes defining patent quality, reassessing examination times, and analyzing the effects of incentives on patent quality[4].

Q4: What is the abstract idea exception in patent law? A4: The abstract idea exception is a legal principle that invalidates patent claims that are directed to abstract ideas without providing a specific means or method that improves the relevant technology[3].

Q5: Why is it important to search international patent databases? A5: Searching international patent databases ensures that the invention has not been previously patented abroad, which is crucial for global patent protection[1].

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Rimon Law - The Importance of Getting the Claim Scope Right in a US Patent Application: https://www.rimonlaw.com/the-importance-of-getting-the-claim-scope-right-in-a-us-patent-application-i/
  3. GAO - Intellectual Property: Patent Office Should Define Quality, Reassess Policies: https://www.gao.gov/products/gao-16-490
  4. Unified Patents Portal - US-20180221327-A1: https://portal.unifiedpatents.com/patents/patent/US-20180221327-A1

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,668,040

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon Therap Us RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ⤷  Try for Free ⤷  Try for Free TREATMENT OF A UREA CYCLE DISORDER ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.